Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ross A. Johnson is active.

Publication


Featured researches published by Ross A. Johnson.


Pharmaceutical Development and Technology | 2000

Influence of peroxide impurities in povidone and crospovidone on the stability of Raloxifene hydrochloride in tablets : Identification and control of an oxidative degradation product

Kerry John Hartauer; Gordon N. Arbuthnot; Steven W. Baertschi; Ross A. Johnson; Wayne Douglas Luke; Neil Pearson; Eugene C. Rickard; Cheryl Ann Tingle; Paul K. S. Tsang; Robert E. Wiens

The purpose of this study was to identify a degradation product in a tablet formulation of raloxifene hydrochloride (R-HCl), delineate the role of excipients in its formation, and develop a rational strategy for its control. The degradant was identified as an N-oxide derivative of the drug substance based upon spectroscopic characterization and chromatographic comparison to the synthetic N-oxide. To identify the factors contributing to the formation of N-oxide, binary mixtures of each excipient with R-HCl were exposed to 125°C in open containers. Raloxifene hydrochloride underwent an order of magnitude increase in conversion to the N-oxide in the presence of two excipients, povidone and crospovidone, as compared with its conversion in the presence of other excipients. To confirm a hypothesis that peroxide impurities in these two excipients contributed to the oxidation of the drug substance, tablet lots were spiked with quantities of H2O2 equivalent to 200, 400, 600, and 800 ppm peroxide over the intrinsic levels present in povidone and crospovidone. A strong correlation was observed between the total peroxide level and the quantity of the N-oxide formed upon accelerated storage. From these experiments a rational limit test for peroxide content in povidone and crospovidone was adopted as part of a control strategy to limit formation of the degradation product.


NeuroImage | 2016

Application of neurite orientation dispersion and density imaging (NODDI) to a tau pathology model of Alzheimer's disease.

Niall Colgan; Bernard Siow; James M. O'Callaghan; Ian F. Harrison; Jack A. Wells; Holly Holmes; Ozama Ismail; Simon Richardson; Daniel C. Alexander; Emily C. Collins; Elizabeth M. C. Fisher; Ross A. Johnson; Adam J. Schwarz; Zeshan Ahmed; Michael J. O'Neill; Tracey K. Murray; Hui Zhang; Mark F. Lythgoe

Increased hyperphosphorylated tau and the formation of intracellular neurofibrillary tangles are associated with the loss of neurons and cognitive decline in Alzheimers disease, and related neurodegenerative conditions. We applied two diffusion models, diffusion tensor imaging (DTI) and neurite orientation dispersion and density imaging (NODDI), to in vivo diffusion magnetic resonance images (dMRI) of a mouse model of human tauopathy (rTg4510) at 8.5 months of age. In grey matter regions with the highest degree of tau burden, microstructural indices provided by both NODDI and DTI discriminated the rTg4510 (TG) animals from wild type (WT) controls; however only the neurite density index (NDI) (the volume fraction that comprises axons or dendrites) from the NODDI model correlated with the histological measurements of the levels of hyperphosphorylated tau protein. Reductions in diffusion directionality were observed when implementing both models in the white matter region of the corpus callosum, with lower fractional anisotropy (DTI) and higher orientation dispersion (NODDI) observed in the TG animals. In comparison to DTI, histological measures of tau pathology were more closely correlated with NODDI parameters in this region. This in vivo dMRI study demonstrates that NODDI identifies potential tissue sources contributing to DTI indices and NODDI may provide greater specificity to pathology in Alzheimers disease.


NeuroImage | 2015

In vivo imaging of tau pathology using multi-parametric quantitative MRI

Jack A. Wells; James M. O'Callaghan; Holly Holmes; Nick M. Powell; Ross A. Johnson; Bernard Siow; Francisco Torrealdea; Ozama Ismail; Simon Walker-Samuel; Xavier Golay; Marilena Rega; Simon Richardson; Marc Modat; Manuel Jorge Cardoso; Sebastien Ourselin; Adam J. Schwarz; Zeshan Ahmed; Tracey K. Murray; Michael J. O'Neill; Emily C. Collins; Niall Colgan; Mark F. Lythgoe

As the number of people diagnosed with Alzheimers disease (AD) reaches epidemic proportions, there is an urgent need to develop effective treatment strategies to tackle the social and economic costs of this fatal condition. Dozens of candidate therapeutics are currently being tested in clinical trials, and compounds targeting the aberrant accumulation of tau proteins into neurofibrillary tangles (NFTs) are the focus of substantial current interest. Reliable, translatable biomarkers sensitive to both tau pathology and its modulation by treatment along with animal models that faithfully reflect aspects of the human disease are urgently required. Magnetic resonance imaging (MRI) is well established as a valuable tool for monitoring the structural brain changes that accompany AD progression. However the descent into dementia is not defined by macroscopic brain matter loss alone: non-invasive imaging measurements sensitive to protein accumulation, white matter integrity and cerebral haemodynamics probe distinct aspects of AD pathophysiology and may serve as superior biomarkers for assessing drug efficacy. Here we employ a multi-parametric array of five translatable MRI techniques to characterise the in vivo pathophysiological phenotype of the rTg4510 mouse model of tauopathy (structural imaging, diffusion tensor imaging (DTI), arterial spin labelling (ASL), chemical exchange saturation transfer (CEST) and glucose CEST). Tau-induced pathological changes included grey matter atrophy, increased radial diffusivity in the white matter, decreased amide proton transfer and hyperperfusion. We demonstrate that the above markers unambiguously discriminate between the transgenic group and age-matched controls and provide a comprehensive profile of the multifaceted neuropathological processes underlying the rTg4510 model. Furthermore, we show that ASL and DTI techniques offer heightened sensitivity to processes believed to precede detectable structural changes and, as such, provides a platform for the study of disease mechanisms and therapeutic intervention.


Neurobiology of Aging | 2016

Imaging the accumulation and suppression of tau pathology using multiparametric MRI

Holly Holmes; Niall Colgan; Ozama Ismail; Da Ma; Nick M. Powell; James M. O'Callaghan; Ian F. Harrison; Ross A. Johnson; Tracey K. Murray; Zeshan Ahmed; Morton Heggenes; Alice Fisher; Manuel Jorge Cardoso; Marc Modat; Simon Walker-Samuel; Elizabeth M. C. Fisher; Sebastien Ourselin; Michael J. O'Neill; Jack A. Wells; Emily C. Collins; Mark F. Lythgoe

Mouse models of Alzheimers disease have served as valuable tools for investigating pathogenic mechanisms relating to neurodegeneration, including tau-mediated and neurofibrillary tangle pathology—a major hallmark of the disease. In this work, we have used multiparametric magnetic resonance imaging (MRI) in a longitudinal study of neurodegeneration in the rTg4510 mouse model of tauopathy, a subset of which were treated with doxycycline at different time points to suppress the tau transgene. Using this paradigm, we investigated the sensitivity of multiparametric MRI to both the accumulation and suppression of pathologic tau. Tau-related atrophy was discernible from 5.5 months within the cortex and hippocampus. We observed markedly less atrophy in the treated rTg4510 mice, which was enhanced after doxycycline intervention from 3.5 months. We also observed differences in amide proton transfer, cerebral blood flow, and diffusion tensor imaging parameters in the rTg4510 mice, which were significantly less altered after doxycycline treatment. We propose that these non-invasive MRI techniques offer insight into pathologic mechanisms underpinning Alzheimers disease that may be important when evaluating emerging therapeutics targeting one of more of these processes.


NeuroImage | 2017

Tissue magnetic susceptibility mapping as a marker of tau pathology in Alzheimer's disease

James M. O'Callaghan; Holly Holmes; Nick M. Powell; Jack A. Wells; Ozama Ismail; Ian F. Harrison; Bernard Siow; Ross A. Johnson; Zeshan Ahmed; Alice Fisher; Soraya Meftah; Michael J. O'Neill; Tracey K. Murray; Emily C. Collins; K Shmueli; Mark F. Lythgoe

Abstract Alzheimers disease is connected to a number of other neurodegenerative conditions, known collectively as ‘tauopathies’, by the presence of aggregated tau protein in the brain. Neuroinflammation and oxidative stress in AD are associated with tau pathology and both the breakdown of axonal sheaths in white matter tracts and excess iron accumulation grey matter brain regions. Despite the identification of myelin and iron concentration as major sources of contrast in quantitative susceptibility maps of the brain, the sensitivity of this technique to tau pathology has yet to be explored. In this study, we perform Quantitative Susceptibility Mapping (QSM) and T2* mapping in the rTg4510, a mouse model of tauopathy, both in vivo and ex vivo. Significant correlations were observed between histological measures of myelin content and both mean regional magnetic susceptibility and T2* values. These results suggest that magnetic susceptibility is sensitive to tissue myelin concentrations across different regions of the brain. Differences in magnetic susceptibility were detected in the corpus callosum, striatum, hippocampus and thalamus of the rTg4510 mice relative to wild type controls. The concentration of neurofibrillary tangles was found to be low to intermediate in these brain regions indicating that QSM may be a useful biomarker for early stage detection of tau pathology in neurodegenerative diseases. HighlightsThe rTg4510 is a mouse model of tauopathy.We applied QSM and T2* Mapping MRI techniques to the rTg4510 in vivo and ex vivo.QSM demonstrated sensitivity to regions of low and intermediate tau burden.QSM may hold potential as a non‐invasive early biomarker of tau pathology.


Tetrahedron | 1994

Conformational analysis of dirithromycin and epi-dirithromycin

John M. McGill; Ross A. Johnson

Abstract The solution conformations of dirithromycin (3) and epi-dirithromycin (4) were determined by NMR spectroscopy and molecular mechanics calculations. Dirithromycin exists in a “folded-in” conformation which is similar to its crystalline conformation, while epi-dirithromycin exists in a ”folded out” conformation which is similar to the crystalline conformation of erythromycin A hydroiodide dihydrate. Included is a discussion of the kinetically versus thermodynamically controlled formation of the remote aminal stereocenter.


Frontiers in Neuroinformatics | 2017

Comparison of In Vivo and Ex Vivo MRI for the Detection of Structural Abnormalities in a Mouse Model of Tauopathy

Holly Holmes; Nick M. Powell; Da Ma; Ozama Ismail; Ian F. Harrison; Jack A. Wells; Niall Colgan; James M. O'Callaghan; Ross A. Johnson; Tracey K. Murray; Zeshan Ahmed; Morten Heggenes; Alice Fisher; M. Jorge Cardoso; Marc Modat; Michael J. O'Neill; Emily C. Collins; Elizabeth M. C. Fisher; Sebastien Ourselin; Mark F. Lythgoe

With increasingly large numbers of mouse models of human disease dedicated to MRI studies, compromises between in vivo and ex vivo MRI must be fully understood in order to inform the choice of imaging methodology. We investigate the application of high resolution in vivo and ex vivo MRI, in combination with tensor-based morphometry (TBM), to uncover morphological differences in the rTg4510 mouse model of tauopathy. The rTg4510 mouse also offers a novel paradigm by which the overexpression of mutant tau can be regulated by the administration of doxycycline, providing us with a platform on which to investigate more subtle alterations in morphology with morphometry. Both in vivo and ex vivo MRI allowed the detection of widespread bilateral patterns of atrophy in the rTg4510 mouse brain relative to wild-type controls. Regions of volume loss aligned with neuronal loss and pathological tau accumulation demonstrated by immunohistochemistry. When we sought to investigate more subtle structural alterations in the rTg4510 mice relative to a subset of doxycycline-treated rTg4510 mice, ex vivo imaging enabled the detection of more regions of morphological brain changes. The disadvantages of ex vivo MRI may however mitigate this increase in sensitivity: we observed a 10% global shrinkage in brain volume of the post-mortem tissues due to formalin fixation, which was most notable in the cerebellum and olfactory bulbs. However, many central brain regions were not adversely affected by the fixation protocol, perhaps due to our “in-skull” preparation. The disparity between our TBM findings from in vivo and ex vivo MRI underlines the importance of appropriate study design, given the trade-off between these two imaging approaches. We support the utility of in vivo MRI for morphological phenotyping of mouse models of disease; however, for subtler phenotypes, ex vivo offers enhanced sensitivity to discrete morphological changes.


Frontiers in Neuroscience | 2017

In Vivo Imaging of Tau Pathology Using Magnetic Resonance Imaging Textural Analysis

Niall Colgan; Balaji Ganeshan; Ian F. Harrison; Ozama Ismail; Holly Holmes; Jack A. Wells; Nick M. Powell; James M. O'Callaghan; Michael J. O'Neill; Tracey K. Murray; Zeshan Ahmed; Emily C. Collins; Ross A. Johnson; Ashley M. Groves; Mark F. Lythgoe

Background: Non-invasive characterization of the pathological features of Alzheimers disease (AD) could enhance patient management and the development of therapeutic strategies. Magnetic resonance imaging texture analysis (MRTA) has been used previously to extract texture descriptors from structural clinical scans in AD to determine cerebral tissue heterogeneity. In this study, we examined the potential of MRTA to specifically identify tau pathology in an AD mouse model and compared the MRTA metrics to histological measures of tau burden. Methods: MRTA was applied to T2 weighted high-resolution MR images of nine 8.5-month-old rTg4510 tau pathology (TG) mice and 16 litter matched wild-type (WT) mice. MRTA comprised of the filtration-histogram technique, where the filtration step extracted and enhanced features of different sizes (fine, medium, and coarse texture scales), followed by quantification of texture using histogram analysis (mean gray level intensity, mean intensity, entropy, uniformity, skewness, standard-deviation, and kurtosis). MRTA was applied to manually segmented regions of interest (ROI) drawn within the cortex, hippocampus, and thalamus regions and the level of tau burden was assessed in equivalent regions using histology. Results: Texture parameters were markedly different between WT and TG in the cortex (E, p < 0.01, K, p < 0.01), the hippocampus (K, p < 0.05) and in the thalamus (K, p < 0.01). In addition, we observed significant correlations between histological measurements of tau burden and kurtosis in the cortex, hippocampus and thalamus. Conclusions: MRTA successfully differentiated WT and TG in brain regions with varying degrees of tau pathology (cortex, hippocampus, and thalamus) based on T2 weighted MR images. Furthermore, the kurtosis measurement correlated with histological measures of tau burden. This initial study indicates that MRTA may have a role in the early diagnosis of AD and the assessment of tau pathology using routinely acquired structural MR images.


Alzheimers & Dementia | 2015

A multiscale MRI approach to investigate novel drug treatment strategies in mouse models of Alzheimer's disease

Ozama Ismail; Holly Holmes; Niall Colgan; Da Ma; Jack A. Wells; Nick M. Powell; James M. O'Callaghan; Ian F. Harrison; Simon Walker-Samuel; Jorge Cardoso; Marc Modat; Elizabeth M. C. Fisher; Sebastien Ourselin; Tracey K. Murray; Zeshan Ahmed; Michael J. O'Neill; Ross A. Johnson; Emily C. Collins; Mark F. Lythgoe

described effects of age on clinical presentation (greater memory impairment in older patients, diffuse cortical deficits in younger patients) and neurodegenerative patterns (medial temporal in lateonset AD and cortical-predominant in early-onset AD). ApoE-ε4 carriers had greater right-parietal and bilateral lateral-temporal retention than non-carriers. Lower MMSE scores predicted greater uptake in inferior/middle frontal gyri and left-temporal pole, consistent with spread of tau into anterior brain regions with advancing disease. These results remained largely unchanged when age, ApoE-ε4 and MMSE were included in a combined model. Decreased performance on modified trailmaking, figure copy, and figure recall tasks was related to increased uptake in right-occipitoparietal visual association cortex, and impaired figure recall also predicted tracer retention in right>left hippocampus (Figure 3). Conclusions:We found preliminary associations between [F]AV1451 binding patterns and age, ApoE-ε4 and domain-specific cognitive performance, mirroring links between these factors and the distribution of neurofibrillary tangles at autopsy. These findings need to be confirmed in larger samples.


Alzheimers & Dementia | 2015

Imaging the efficacy of microtubule stabilizing agent epothilone d in the rtg4510 mouse model of tauopathy

Ozama Ismail; Ian F. Harrison; Holly Holmes; Niall Colgan; Jack A. Wells; James M. O'Callaghan; Nick M. Powell; Da Ma; Sebastien Ourselin; Simon Walker-Samuel; Tracey K. Murray; Alice Fisher; Zeshan Ahmed; Michael J. O'Neill; Ross A. Johnson; Emily C. Collins; Mark F. Lythgoe

Ozama Ismail, Ian F. Harrison, Holly Holmes, Niall Colgan, Jack A. Wells, James M. O’Callaghan, Nicholas M. Powell, Da Ma, Sebastien Ourselin, Simon Walker-Samuel, Tracey K. Murray, Alice Fisher, Zeshan Ahmed, Michael J. O’Neill, Ross A. Johnson, Emily C. Collins, Mark F. Lythgoe, University College London, London, United Kingdom; Centre for Medical Image Computing, University College London, London, United Kingdom; Eli Lilly and Company, Surrey, United Kingdom; Eli Lilly and Company, Indianapolis, IN, USA. Contact e-mail: [email protected]

Collaboration


Dive into the Ross A. Johnson's collaboration.

Top Co-Authors

Avatar

Jack A. Wells

University College London

View shared research outputs
Top Co-Authors

Avatar

Mark F. Lythgoe

University College London

View shared research outputs
Top Co-Authors

Avatar

Ozama Ismail

University College London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Holly Holmes

University College London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ian F. Harrison

University College London

View shared research outputs
Top Co-Authors

Avatar

Niall Colgan

University College London

View shared research outputs
Researchain Logo
Decentralizing Knowledge